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http://www.biomedcentral.com/1471-2377/13/100CASE REPORT Open AccessSpontaneous intracranial hemorrhage as an initial
manifestation of primary Sjögren’s syndrome:
a case report
Guo-Qiang Wang*† and Wei-Wei Zhang†Abstract
Background: Sjögren’s syndrome can involve the central nervous system; however, spontaneous intracranial
hemorrhage has rarely been reported as the initial manifestation.
Case presentation: We report a 39-year-old woman with primary Sjögren’s syndrome presenting with intracranial
hemorrhage. The diagnosis of primary Sjögren’s syndrome was based on the presence of ocular dryness, salivary
gland secretory and excretory dysfunction confirmed with dynamic tracer emission CT, and positive anti-Sjögren’s
syndrome A and anti-Sjögren’s syndrome B antibodies.
Conclusion: Primary Sjögren’s syndrome can present with variable central nervous system signs, which may
precede the classic sicca symptoms. Therefore, Sjögren’s syndrome-associated indicators should be investigated in
patients without the common risk factors for stroke who present with spontaneous intracranial hemorrhage.
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Sjögren’s syndrome (SS) is a common autoimmune dis-
ease. The histopathological hallmark is periductal lympho-
cytic infiltration of the exocrine glands, mainly the salivary
and lacrimal glands, which results in loss of secretory
function. The annual incidence has been estimated at 3.9–
6.0 per 100,000 population [1,2]. SS has a marked female
preponderance with a female-to-male ratio of 13:1. It also
features a later age at onset, with a median age of 54 years
for women and 58 years for men at the first diagnosis [3].
This syndrome is classified as primary SS (pSS) in the ab-
sence of other autoimmune diseases, and as secondary
SS when it is associated with other autoimmune diseases
such as rheumatoid arthritis, scleroderma, systemic lupus
erythematosus, AIDS, hepatitis C infection, pre-existing
lymphoma sarcoidosis, graft-versus-host disease, or the
use of anticholinergic drugs.
The neurological manifestations of pSS involve both
the peripheral and central nervous systems. Peripheral* Correspondence: wgqbj@163.com
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distribution, and reproduction in any mediumnervous system involvement is considered the most com-
mon neurological manifestation in pSS, and is characterized
by predominantly sensory or occasionally mixed neuropa-
thies, and mononeuritis multiplex. Central nervous system
involvement occurs in 5.8–68% of pSS patients [4,5] and, in
most cases, neurological manifestations precede the sicca
symptoms [6]. Central nervous system lesions in pSS vary
from diffuse involvement, which manifests as cognitive def-
icits or meningoencephalitis, to focal involvement, which
presents with similar symptoms to multiple sclerosis or
neuromyelitis optica [7]. SS-associated infarction seldom
occurs with stroke-like features such as aphasia or hemiple-
gia [5] and SS is even more rarely complicated with severe
cerebral artery lesions, particularly hemorrhagic stroke. We
report a case of a patient with pSS who presented with
intracranial hemorrhage (ICH).
Case presentation
After suffering from acute headache for 2 h while washing
clothes, a 39-year-old woman was admitted to the Depart-
ment of Neurology, General Hospital of Beijing Military
Region, in September 2012. The patient had no history of
hypertension, coagulation disorders, or arthralgia, andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mission, her general examination was normal except for
mild hypertension (148/90 mmHg). The neurological
examination revealed positive Kernig’s sign only, without
motor or sensory deficit. An urgent brain CT (Figure 1)
showed hemorrhage in the left hippocampus, which ex-
tended into the ventricular system. Mannitol 250 mL was
administered every 8 h for 1 week. Her headache gradually
eased, the blood pressure returned to the normal range,
and Kernig’s sign disappeared.
All of the additional examination results were normal,
including ambulatory blood pressure and electrocardio-
gram; chest CT; cardiac ultrasonography; and examina-
tions of the digestive, urinary, and uterine systems, and the
breasts and appendages. Vision in the left and right eyes
was 0.6 and 0.5, respectively. Schirmer’s tear test results in
both eyes were <2 mm in 5 min (normal >15 mm); tear
breakup time was 2 s (normal ≥10 s); and punctate fluores-
cein staining was >10 (normal <10).Figure 1 Brain CT obtained on the day of onset. The image shows hem
into the ventricular system (A-F, white arrows).The results of routine laboratory studies were also at
normal levels, including complete blood cell count, co-
agulation, liver function, kidney and thyroid, lipids,
glucose, glycosylated hemoglobin, C-reactive protein,
and anti-O chain. Serological tests for HBsAg, hepatitis
C virus, human immunodeficiency virus, syphilis, and
tumor markers were negative. Erythrocyte sedimentation
rate (ESR) was 62 mm/1st h; rheumatoid factor, 701 IU/mL
(normal <25); antibody SS-A titer, 95 ng/mL; SS-B,
58 ng/mL; and recombinant Ro-52, 83 ng/mL (normal <10).
Immunoglobulin (Ig) G was 18.7 g/L (normal 6–16); IgA,
6.86 g/L (normal, 0.4–3.3); IgM, 2.14 g/L (normal, 0.4–2.6);
complement C3, 0.44 g/L (normal, 0.85–1.93); and C4,
0.13 g/L (normal, 0.12–0.36). Other auto-antibodies, in-
cluding anti-β2-glycoprotein-I, anti-cardiolipin, anti-TB,
and paraneoplastic antibody (anti-Hu, Yo, Ri, NMDA)
were negative.
Brain MRI (Figure 2) performed 5 days after admission
confirmed the diagnosis of hemorrhage in the left uncusorrhage in the left hippocampus (A, B, black arrow), which extends
Figure 2 Brain MRI obtained 5 days post-onset. Axial T1, T2, T2-FLAIR, and DWI (A–D) show an abnormal high signal within the left lateral
uncus (hippocampus) (arrows). On T2 star-weighted angiography imaging (E), the lesion shows markedly low signal intensity (black arrow) with a
hyperintense core (white arrow). These findings indicate that the left hippocampal hemorrhage was subacute. Sagittal T1 (F) shows multiple
lacunar low signals in the parietal and periventricular areas (arrows), suggesting multiple lacunar infarction in the cerebral hemispheres.
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cerebral hemispheres.
Cerebral angiography revealed occlusion of the terminal
portion of the left internal carotid artery (Figure 3A and B).
Mild collateral circulation from the right internal ca-
rotid artery (Figure 3C) and the left posterior cerebral
artery (Figure 3D) to the left middle cerebral artery
region were present,and moyamoya vessels were slightly
seen (Figure 3A, black arrow). No aneurysm, arteriovenous
malformation or obvious vascular wall irregularity was
found. The cerebral venous system was not involved.
Salivary gland dynamic tracer emission CT with
99mTc-sodium pertechnetate (Figure 4) showed de-
creased uptake in the left parotid and both subman-
dibular glands, as well as reduced excretion in both
sets of glands.Based on the abnormal laboratory findings, the patient
was diagnosed with pSS-associated cerebral vasculitis with
ICH extending into the ventricular system, and with occlu-
sion of the terminal portion of the left internal carotid ar-
tery accompanied by moyamoya vessels (quasi-moyamoya
disease), as well as with multiple lacunar infarctions.
After the diagnosis, methylprednisolone 160 mg/day
was administered by intravenous injection for 1 week,
with oral leflunomide 10 mg/day. Follow-up CT was
performed 2 weeks after admission and revealed that the
hemorrhage was completely absorbed with no evidence
of hydrocephalus; therefore the patient was discharged.
At the 3-month follow-up, the patient was completely
independent, with no discomfort, and normal physical
examination findings. Laboratory tests showed positive
results for SS-A/SS-B/Re-52 antibodies, and elevated
Figure 3 Cerebral angiography. The images show occlusion of the terminal portion of the left internal carotid artery (A, B, white arrow). Mild
collateral circulation within the left middle cerebral artery region (C, D, white arrow) was also seen. The collateral circulation arose from the right
internal carotid artery (C) and the left posterior cerebral artery (D) to the left middle cerebral artery region. A small number of moyamoya vessels
can be seen (A, black arrow).
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that of the initial results.Conclusion
Only five case of pSS-associated ICH have been reported
[8-12]. Unlike our case, all of the five reported cases had a
clear history of pSS prior to the ICH, and none had ICH as
the first manifestation of pSS. Four patients developed an-
eurysms leading to subarachnoid hemorrhage [9-12].Currently, vasculitis is a recognized feature of SS and is
the pathological basis of the nervous system damage. Any
vessels in the brain or spinal cord can be involved [5]. SS-
associated systemic vasculitic manifestations occur in
approximately 5–10% of SS patients [13] and two histo-
pathological types have been suggested according to the
type of the infiltrating cell: the neutrophilic type and the
mononuclear cell type [14]. In SS-associated vasculitis,
there is direct vessel wall invasion by neutrophilic or
mononuclear cells, hyperplasia of endothelial and smooth
Figure 4 Salivary gland dynamic tracer emission CT with 99m Tc-sodium pertechnetate. A gustatory stimulus of vitamin C tablets begins
at 20 min. The uptake capability of both submandibular and the left parotid glands is lower than that of the right parotid (A). Radiotracer
development after the stimulation of vitamin C tablets at 20 min showed neither obvious decline in both sets of the glands nor any visible
accumulation in the oral cavity (B). Parotid time-activity curve shows normal uptake on the right side (C), but decreased on the left (D), and no
excretion on both sides after stimulation with vitamin C (blue line). OC: oral cavity; RP: right parotid gland; LP: left parotid gland; RS: right
submandibular; LS: left submandibular.
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pathological factors alter or destroy the normal struc-
ture of the vessel wall, and result in vessel lumen occlu-
sion, or wall rupture due to changes in local pressure at
a weak point in the vessel wall [14]. Abnormal collateral
vessels (moyamoya vessels) at the base of the brain may
develop in autoimmune diseases such as SS [8,15]. In
such conditions, the abnormal vascular network is
termed quasi-moyamoya disease [16]. Moyamoya ves-
sels are prone to thrombosis or hemorrhage due to fi-
brin deposits in their walls, fragmented elastic laminae,
attenuated media, and microaneurysm formation [17].It is well known that hemorrhagic stroke from moyamoya
vessels occurs predominantly in adult moyamoya disease
patients. If hypoperfusion is confirmed, bypass surgery
may be considered to prevent rebleeding [16].
The most common serologic finding in SS is hy-
pergammaglobulinemia, which is found in 80% of pSS
patients [18]. The elevated immunoglobulin levels in
SS patients contain a number of autoantibodies, includ-
ing rheumatoid factors, and antinuclear, anti-SS-A and
anti-SS-B antibodies [3]. The presence of these auto-
antibodies is closely related to the occurrence of
vasculitis [14].
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average diagnostic delay of 3–8 years [19,20], even though
100% of pSS patients have exocrine gland involvement.
Patients presenting with sicca symptoms account for fewer
than half of all pSS patients [20].
Our patient’s sicca symptoms were not obvious
clinically either before or after hemorrhage. Currently,
the diagnosis of pSS is based on the following: high
titers for anti-SS-A/Ro, SS-B/La, and recombinant
Ro-52 antibodies and rheumatoid factor; elevated IgG
and IgA; accelerated ESR; decreased exocrine glandular
function; no trace of other autoimmune or infectious
disease; and the revised classification criteria for
Sjögren’s syndrome proposed by the American-
European Consensus Group [21]. We hypothesized
that in our patient, the pSS-associated vasculitis might
have contributed to the development of the asymptom-
atic occlusion of the left terminal portion of the in-
ternal carotid artery and the subsequent development
of moyamoya vessels, ICH, and multiple lacunar
infarctions.
Vasculitis-associated clues should be carefully investi-
gated in adult female patients with stroke, particularly
those without common stroke risk factors, such as hyper-
tension or coagulopathy.Informed consent
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